Vesugen peptide: what the Khavinson vascular tripeptide is, what the studies show and what is unknown

Vesugen is the trade name for the tripeptide Lys-Glu-Asp: lysine, glutamic acid and aspartic acid joined in that order. In single-letter code it is KED, and the recent papers from its developers mostly call it the KED peptide. Some of the older culture studies use the laboratory code T-38 for the same sequence ^{[14] [15]}. The name is transliterated from Russian in two ways, Vesugen and Vezugen, and both appear in PubMed abstracts ^{[4] [6]}. Sellers list it as the vesugen bioregulator or vesugen vascular peptide.

It is one of the short peptides designed by Vladimir Khavinson’s group at the St Petersburg Institute of Bioregulation and Gerontology. The group’s method, described in a 2002 overview, was to analyse the amino acid composition of a polypeptide extract of a given organ and then synthesise a two-, three- or four-amino-acid peptide meant to reproduce that organ’s tissue-specific activity ^[18]. Vesugen is the vessel peptide in this series, alongside vilon for the thymus, epitalon for the pineal gland, cardiogen for the heart and pancragen for the pancreas.

Almost every paper about vesugen has Khavinson or a close collaborator among the authors. Most were published in the Bulletin of Experimental Biology and Medicine, a translated Russian journal indexed in PubMed, or in Advances in Gerontology, a Russian journal with English abstracts only. A handful of more recent studies involve co-authors in Italy and at Moscow State University, but no group without a connection to the developers has, to our knowledge, published on KED. That is the context for everything that follows.

The developers propose that KED acts on blood vessel cells by changing gene expression. In cultures of vascular endothelial cells from young and old animals, vesugen increased the proliferation marker Ki-67, which falls with age, and molecular docking suggested it could bind a CATC motif in the core promoter of the MKI67 gene; the authors concluded that the vasoprotective effect they had seen in older people could work through this route ^[1]. A 2016 study in cultured endothelium from normal, atherosclerotic and restenotic vessels reported that KED normalised endothelin-1 expression, which rises in atherosclerosis, restored connexin expression between cells and increased sirtuin-1 ^[2]. An earlier culture study, using the code T-38 for the tripeptide, reported increased Ki-67, reduced p53 and reduced E-selectin, an adhesion molecule involved in plaque formation ^[3].

Beyond blood vessels, the same tripeptide is reported to act on nervous, endocrine and immune tissue. In organotypic cultures, Lys-Glu-Asp lowered p53 and raised Ki-67 in pineal gland tissue, more so in cultures from old animals, and induced the lymphocyte marker CD5 and macrophage marker CD68; the same paper reported that it modulated associative learning in honey bees ^[8]. KED and pinealon (Glu-Asp-Arg) increased serotonin expression in ageing brain cortex cultures, and docking suggested a CCTGCC sequence in the tryptophan hydroxylase gene as the target ^[9]. In human mesenchymal stem cells, KED at nanomolar concentrations raised IGF1 and NF-kB expression, lowered FOXO1 by 1.6- to 2.3-fold, and had opposite effects on TNKS2 in two different ageing models ^[12].

All of these mechanism claims rest on cell culture and computer docking from one group. The idea that a three-amino-acid peptide enters the nucleus and selects specific promoters is possible in principle but has not been demonstrated in living tissue by an independent laboratory, and no receptor or binding partner for KED has been identified.

Blood vessels and atherosclerosis: the vascular claims rest on the endothelial culture studies above, which report more proliferation and less E-selectin, endothelin-1 and p53 in ageing or diseased endothelium ^{[1] [2] [3]}. There is no animal study of vesugen in an atherosclerosis model with measured plaque outcomes in PubMed, and no human imaging or event data.

Brain and memory: the developers’ 2021 review states that oral KED improved memory and attention in elderly people with functional central nervous system disorders and restored synaptic plasticity in a cell model of Alzheimer’s disease, and summarises the group’s findings that KED regulates genes for cell ageing (p16, p21), neuronal differentiation (nestin, GAP43) and Alzheimer’s-related pathways (SUMO, APOE, IGF1) ^[7]. A 2019 study with an Italian group found that KED alone, and a mixture of KED with AED, KE and AEDG, increased GAP43 and nestin in human periodontal ligament stem cells, markers of early neuronal differentiation ^[11]. A 2024 study used a newer model, cortical neurons induced directly from the skin fibroblasts of elderly donors, and found that KED, pinealon and epitalon all increased dendrite number and length; the tripeptides had no effect on mitochondrial or lysosomal activity or on p16, and only pinealon reduced oxidative DNA damage ^[10]. The developers’ own 2020 review lists KED among peptides that activate neural differentiation ^[19].

Skin and regeneration: in skin explants from old rats, T-38 (Lys-Glu-Asp) was the tripeptide with the clearest stimulatory effect on proliferation, associated with less p53 expression ^[14]. In ageing human skin fibroblasts, KED, KE, AED and AEDG all reduced MMP-9 and increased Ki-67 and CD98hc ^[13]. In prostate fibroblast cultures, vesugen stimulated the differentiation factors CXCL12 and WEGC1, more strongly in aged cultures ^[16]. Immune tissue: T-38 at 0.05 ng/mL stimulated the growth zone of spleen explants and prevented the suppression of proliferation caused by 1 mg/mL cyclophosphamide ^[15]. Pancreas: in old irradiated rats, T-38 activated post-irradiation regeneration and was reported to restore endocrine homeostasis in the pancreas ^[17].

Taken together, this is a body of positive cell and tissue results across many organs, which is characteristic of the whole Khavinson series and is itself a reason for caution: a peptide reported to stimulate proliferation in vessels, skin, prostate, spleen, pancreas and brain is being credited with a very general effect, and general effects are the easiest to produce by chance in small culture experiments.

There is no randomised, placebo-controlled trial of vesugen, and no entry for it, under either spelling, on ClinicalTrials.gov as of September 2026. Three Russian clinical reports exist, all in Advances in Gerontology, all without a placebo group.

Erectile dysfunction: the vesugen erectile dysfunction report most often quoted by sellers is a 2014 paper from a St Petersburg military medical centre. It described 41 patients with vasculogenic erectile dysfunction, attributed to atherosclerosis, treated with Vezugen as monotherapy. Blood flow in the main penile arteries was measured before and after treatment, and the authors reported significant improvement in both clinical scores and objective flow measurements ^[4]. There was no control group, so regression to the mean and placebo effects cannot be separated from any drug effect, and the abstract does not give the dose, route or duration.

Geriatric polymorbidity: a 2015 study in Yekaterinburg gave Pinealon and Vesugen to 32 people aged 41 to 83 with multiple chronic conditions and organic brain syndrome in remission, and assessed biological age indicators. The authors reported an anabolic effect and slowed biological ageing, with vesugen showing the larger effect, but they also found pro-oxidant activity on a chemiluminescence assay and a significant fall in circulating CD34-positive haematopoietic stem cells, which they interpreted as suppression of blood cell formation ^[5]. This is one of the few reports in the entire series to record an unfavourable laboratory finding, and it deserves more attention than the positive headline.

Occupational stress: a 2012 study compared 150 lorry drivers with 150 metalworkers for neurotic and adaptation disorders and reported that a combination of pinealon and vezugen improved psychoemotional scores and stress resistance in the drivers ^[6]. The abstract does not describe randomisation or a placebo. The developers’ 2021 review also asserts that oral KED improved memory and attention in elderly people, citing the group’s own earlier work ^[7].

No study has measured onset or duration of effect in people. The erectile dysfunction report measured blood flow after a course of treatment of unstated length ^[4], and the geriatric study assessed biological age after the peptide course ^[5]. In culture, gene expression changes are measured within days of adding the peptide ^{[1] [12]}. Claims that vesugen improves circulation within a set number of weeks are not supported by any published time-course.

The figures below describe what published studies used. They are not recommendations, and no human dose has been established in a controlled trial. In cell and tissue culture, the effective concentration reported for T-38 was 0.05 ng/mL in spleen explants ^[15], and KED was active at nanomolar concentrations in mesenchymal stem cells ^[12]. The rat and human reports do not give doses in their English abstracts ^{[4] [5] [17]}. The 2021 review refers to oral KED in elderly people without stating a dose ^[7].

In Russia, KED is sold in capsule form under the Vesugen name, and the labelled amounts on such products are not derived from a published dose-finding study. Research suppliers elsewhere sell it as a lyophilised powder, usually in 10 to 20 mg vials. For converting vial contents to a concentration for a laboratory protocol, use the peptide calculator or its vesugen page.

The Russian clinical reports describe vesugen as a preparation taken by mouth, and the developers’ review refers to oral application ^[7]. The developers have modelled the transport of their short peptides through the intestinal amino acid and peptide transporters LAT1, LAT2 and PEPT1, but that is a docking study, not a pharmacokinetic one ^[20]. We found no published measurement of KED in human blood after any route of administration, so bioavailability, half-life and tissue distribution are unknown. Research suppliers sell the powder for reconstitution; the culture and animal literature offers no guidance on injected doses in people.

No systematic safety study of vesugen has been published. The 2015 geriatric report is the most informative: alongside its positive findings, it recorded pro-oxidant activity and a significant drop in CD34-positive haematopoietic progenitor cells in the blood of treated patients ^[5]. The authors did not treat this as a reason to stop using the peptide, but a fall in circulating stem cells after a course of an unlicensed peptide in elderly patients with multiple conditions is exactly the kind of signal that a controlled trial would be needed to interpret. It has not been followed up.

The mechanism studies describe KED as pro-proliferative in endothelium, skin, prostate and spleen and as raising NF-kB and IGF1 expression in stem cells ^{[1] [12] [16]}. The developers report these as regenerative or geroprotective effects; whether a peptide that promotes proliferation in prostate fibroblasts and endothelium is neutral for people with, or at risk of, tumours or proliferative vascular disease has not been examined. Vesugen is not on the FDA’s list of compounding bulk substances that may present significant safety risks ^[21]; that reflects that nobody nominated it, not that it has been reviewed.

Vesugen is not an approved medicine in the UK, US, EU, Canada or Australia. Any product marketed for human use with claims about blood vessels, circulation or ageing would be treated as a medicine in the UK regardless of a research-use label, and the MHRA has licensed no such product. In the US it is not an FDA-approved drug and has not appeared on the compounding category 2 list ^[21]. In Russia it is sold as a dietary supplement rather than a registered medicine; a Russian supplement listing confers no status elsewhere. We have not confirmed its standing under the WADA Prohibited List.

For the rules on buying and holding research peptides in your country, see the legal status overview, the UK page and the US page.

Vesugen is supplied as a freeze-dried powder. It contains no cysteine, methionine or tryptophan and is chemically robust for a peptide, but the standard rules apply: keep the sealed vial cold, dry and away from light, refrigerate reconstituted solution and use it within a limited period. See how to store peptides and the guide to bacteriostatic water.

A three-amino-acid peptide is cheap to synthesise, so price is a poor guide to quality. Compare vesugen prices across the stores we track, including UK listings and US listings. Read how to read a peptide COA first: a certificate for vesugen should show a measured mass of about 390 g/mol, and because Lys-Glu-Asp is easy to confuse with related sequences such as Ala-Glu-Asp or Glu-Asp-Arg, mass spectrometry matters more than HPLC purity alone. Our third-party tested suppliers list shows which stores publish independent tests.

Vesugen is often sold in a stack with pinealon, reflecting the two Russian studies that combined them ^{[5] [6]}. For the other tissue-specific peptides in the same family, see pinealon, cartalax, thymalin and thymosin alpha-1, which is a different, much longer immune peptide sometimes grouped with them. Our guide to third-party peptide testing explains what independent testing can and cannot tell you.